TRT and BPH IPSS Trends from Recent Trials

Key takeaways

• Across modern studies including the 5,204-participant TRAVERSE trial, TRT did not worsen overall BPH/LUTS; IPSS changes were comparable to placebo.
• TRAVERSE found low absolute prostate event rates with no significant differences in high-grade prostate cancer, BPH surgery, or new BPH medications versus placebo.
• PSA typically rises modestly early during TRT and then stabilizes around 12 months; a minor trend toward urinary retention warrants vigilance.
• Most trials excluded men with severe LUTS or higher prostate cancer risk, so individualized assessment and monitoring remain essential.
• In 2025, the FDA removed the boxed cardiovascular warning and incorporated TRAVERSE findings while retaining monitoring guidance and limitations of use.

Overview

For years, men considering testosterone replacement therapy (TRT) have asked a simple, important question: will TRT make my prostate symptoms worse? Newer data—including the large TRAVERSE trial completed in 2023 and recent FDA labeling changes in 2025—offer a clearer, more reassuring answer for many men with hypogonadism.

In short: in appropriately selected patients, recent trials do not show overall worsening of benign prostatic hyperplasia (BPH) or lower urinary tract symptoms (LUTS) with TRT. International Prostate Symptom Scores (IPSS) tend to remain stable—and sometimes improve—while small, expected rises in PSA are typically seen early and then plateau. At the same time, caution remains prudent for men with severe symptoms or higher prostate cancer risk, and monitoring still matters.

Why prostate symptoms are central to TRT decisions

BPH and LUTS—such as weak stream, hesitancy, urgency, nocturia, and incomplete emptying—are common in midlife and older men. The IPSS is a seven-question symptom scale (plus a quality-of-life item) widely used to grade LUTS burden in clinical settings:

• Mild: 0–7
• Moderate: 8–19
• Severe: 20–35

Historically, many men and clinicians worried that restoring testosterone might fuel prostate growth and worsen LUTS. This concern stemmed from the prostate’s androgen sensitivity and early-era studies with small samples and mixed designs. Over the last 10–20 years, more rigorous trials and registries have refined the picture, particularly for men with confirmed hypogonadism and mild-to-moderate symptoms.

What the TRAVERSE trial adds

TRAVERSE is a large, placebo-controlled cardiovascular outcomes study that enrolled 5,204 men aged 45–80 with hypogonadism. Men with higher baseline prostate cancer risk (e.g., PSA ≥3 ng/mL) were excluded. Over 14,304 person-years of follow-up, the trial assessed both cardiovascular and prostate-related outcomes, including IPSS, PSA changes, acute urinary retention, BPH interventions, and prostate cancer diagnoses.

What stands out for LUTS/BPH:

• IPSS: Changes over time were similar between the TRT and placebo groups—no signal of overall LUTS worsening attributable to testosterone therapy.
• Prostate events: Low absolute rates with no significant differences between groups in high-grade prostate cancer, acute urinary retention, BPH surgery, or initiation of new BPH medications.
• PSA dynamics: PSA increased more in the TRT arm, but the mean rise was small and largely stabilized after roughly 12 months.

Notably, investigators observed a minor trend toward urinary retention; however, it did not translate into significant differences in hard endpoints versus placebo. This nuance is key: while overall findings are reassuring, clinicians and patients should still pay attention to evolving urinary symptoms—particularly early in therapy or in men with pre-existing voiding issues.

Beyond prostate endpoints, TRAVERSE also reported no increased major cardiovascular risk with TRT (hazard ratio 0.96; 95% CI 0.78–1.17). These data informed the FDA’s February 2025 testosterone label update, which removed the boxed cardiovascular warning and incorporated the trial’s results while preserving important safety monitoring guidance.

What earlier evidence showed

TRAVERSE aligns with a broader body of research spanning prospective trials and real-world registries:

• Systematic and narrative reviews of 1995–2015 trials (35 studies) found no meaningful worsening of IPSS or prostate size among men on TRT with mild LUTS. Some studies even showed statistically significant IPSS improvements by one year.
• Longitudinal registry data have reported sustained IPSS improvement during TRT over multi-year follow-up in hypogonadal men receiving ongoing care.

What explains potential improvement? Hypogonadism can overlap with metabolic syndrome, obesity, and sleep disturbances, which themselves influence LUTS. In some men, better energy, weight changes, or improved sexual function while on TRT might translate into improved perception of urinary symptoms or related quality of life. Still, these are associations rather than proven causal pathways, and not all men experience symptom gains.

PSA on TRT: What to expect and why it matters

A small rise in PSA during the first year of TRT is common and was observed again in TRAVERSE. In the aggregate, this increase tends to be modest and stabilizes after about 12 months. Why?

• Physiologic androgen restoration can stimulate prostate tissue activity to a degree, which may nudge PSA upward.
• For men with low baseline testosterone, returning to eugonadal levels may “normalize” PSA within a safe range.

What matters most is the pattern: a small, early increase that plateaus is expected; a sharp or continuing rise needs prompt clinical attention. The FDA and clinical guidelines emphasize routine PSA monitoring on TRT. That does not mean PSA changes are dangerous by default—it means they should be interpreted in the context of age, symptoms, digital rectal exam findings, medication use, and risk factors.

Practical implications for men considering TRT

For many hypogonadal men with mild-to-moderate LUTS and low baseline prostate cancer risk, the best current evidence suggests that TRT is unlikely to worsen day-to-day urinary symptoms. In several studies, IPSS even improved over time. That said, good practice still involves careful baseline assessment and structured follow-up. Consider discussing the following topics with your clinician:

• Baseline status:
  • Symptom burden using a validated questionnaire such as the IPSS
  • PSA and prostate cancer risk assessment consistent with guidelines
  • Coexisting urinary factors (e.g., hydration habits, caffeine/alcohol use, constipation, sleep apnea)
• Concurrent medications and conditions:
  • Alpha-blockers, 5-alpha-reductase inhibitors, PDE5 inhibitors, diuretics, anticholinergics
  • Metabolic health factors that can affect LUTS and overall well-being
• Early-treatment expectations:
  • Mild PSA rise may occur and often stabilizes within a year
  • Most men do not see worsening of urinary symptoms; a subset may experience change and warrant closer evaluation
• When to report symptoms promptly:
  • Acute urinary retention (sudden inability to urinate)
  • New or rapidly worsening LUTS, hematuria, fever, or pelvic pain
• Monitoring:
  • Regular symptom check-ins (including IPSS or similar tools)
  • PSA and hematocrit monitoring at intervals aligned with clinical guidelines and the updated FDA labeling
  • Reassessment of therapy goals and tolerability over time

For men with severe LUTS at baseline (often IPSS ≥20), the data are more limited because many trials—including TRAVERSE—excluded this group. That does not mean TRT is unsafe in such cases; it means the evidence is thinner, the likelihood of confounding is higher, and shared decision-making with a urologist may be especially important.

What we still don’t know

Important questions remain open:

• Long-term LUTS trajectories beyond 3–5 years, especially in men with severe symptoms at baseline or those who develop new urinary conditions over time
• Whether specific TRT formulations (injectables vs gels vs pellets) meaningfully differ in LUTS or PSA trajectories
• How aromatization to estradiol and metabolic changes (weight loss, improved insulin sensitivity) interact with LUTS
• Optimal monitoring cadence tailored to individual risk profiles

As higher-quality, longer-term data accumulate, these issues will become clearer. For now, clinicians typically personalize TRT decisions using current evidence, individual goals, and urologic risk factors.

The FDA’s 2025 label update: The bigger safety context

On February 28, 2025, the FDA issued class-wide labeling changes for testosterone products:

• Removal of the boxed warning for adverse cardiovascular outcomes, reflecting TRAVERSE’s finding of no increased major cardiovascular risk
• Inclusion of TRAVERSE prostate-safety observations (low incidence of high-grade prostate cancer, acute urinary retention, invasive procedures, or new BPH medications; no significant IPSS differences versus placebo)
• Continued emphasis on appropriate patient selection, monitoring of PSA and hematocrit, and the limitation of use for age-related hypogonadism

For patients, the update does not imply risk-free therapy; rather, it aligns labeling with contemporary evidence and underscores the need for ongoing, individualized risk–benefit evaluation.

How Taurus Meds approaches TRT and prostate symptoms

At Taurus Meds, safety and clarity guide our TRT care model:

• Thoughtful screening: We review symptom history, baseline IPSS, PSA, and relevant risk factors before initiating therapy.
• Evidence-based monitoring: We track PSA and hematocrit over time and coordinate with your primary care clinician or urologist when needed.
• Realistic expectations: We discuss what studies show about TRT and LUTS/BPH—no promise of symptom improvement, no hype, and no shortcuts.
• Responsive follow-up: If urinary symptoms change, we assess promptly and adjust plans in collaboration with your care team.

Our goal is to help you make informed choices and to manage TRT thoughtfully with the latest data in mind.

Bottom line

For appropriately selected men with hypogonadism, current evidence indicates that TRT does not generally worsen BPH or day-to-day lower urinary tract symptoms. IPSS tends to remain stable—sometimes improving—and while PSA often rises modestly early on, it typically plateaus within a year. A small signal toward urinary retention reminds us that vigilance is still wise, particularly in men with pre-existing voiding issues.

The 2025 FDA label update reflects these data, removing the boxed cardiovascular warning and reinforcing prudent monitoring. Severe baseline LUTS, elevated PSA, or higher prostate cancer risk call for more cautious, individualized decision-making and, often, urology input.

If you are exploring TRT, consider your symptom profile, risk factors, and long-term goals—and partner with a clinician who treats monitoring as part of care, not an afterthought.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional with any questions regarding a medical condition or treatment.

Sources

• PubMed Central review on TRT and LUTS/BPH (2015)
• Renal & Urology News: Testosterone therapy and LUTS/BPH
• JAMA Network Open: TRAVERSE trial main results
• FDA: 2025 class-wide labeling changes for testosterone products